Posts Tagged ‘cypb’

CYPB spreads wings, C solid, MOTR in reverse

Wednesday, December 15th, 2010

Cypress Bioscience (NasdaqGM: CYPB) jumped 12.2% to$6.45, on volume of 8,570,704, or 16 times its full-day average, after it agreed to be acquired by Ramius LLC and Royalty Pharma for about $255 million in cash, ending a takeover battle that began in July.

Citigroup (NYSE: C) traded in 155,455,525 shares, making good headway on its daily average of 539,270,000 shares. Share prices retreated 0.53 per cent, however, Wednesday, to $4.66.

Motricity Inc. (NasdaqGM: MOTR) backtracked 13.53 percent in Wednesday morning trading at $18.40. Volume of 3,277,545 shares tramped its full-day average of 559,200. MOTR, based in Bellevue, Wash., is a leading mobile data solutions provider exclusively focused on the rapidly growing mobile Internet market.

Cypress Bioscience, Inc. (CYPB) – Buzz Stock of the Day

Monday, July 19th, 2010

Warning: fopen(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home3/taylor/public_html/ on line 38

Warning: fopen( failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home3/taylor/public_html/ on line 38

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in /home3/taylor/public_html/ on line 39

Warning: fclose() expects parameter 1 to be resource, boolean given in /home3/taylor/public_html/ on line 40

Shares of drug maker Cypress Bioscience, Inc. (Nasdaq: CYPB) rallied as much as 41 percent from Friday’s closing price, in morning trading on Monday after hedge fund, Ramius offered to buy the company for about $154 million, or $4.00 a share in cash.

Ramius currently owns 9.9 percent of Cypress’ common stock. The offer of $4.00 per share is a 60 percent premium over Friday’s closing price of $2.50.


In addition to the all-cash offer, Ramius also stated  that it would consider an acquisition structure that would allow management to continue the development of the recently acquired antipsychotic drug, BL-1020 if they are able to fund the required financing for the Phase IIb trial themselves or from a third party financing source.

In late June, Cypress Bioscience, Inc. entered ¬†into an exclusive North American license for the development and commercialization of BioLineRx’s novel antipsychotic, BL-1020, a treatment for schizophrenia. Specific terms of the transaction were not disclosed, but the total upfront payment to BioLineRx was $30 million, with total potential clinical and regulatory milestones of up to $160 million through to approval in the United States, potential commercial milestones of $85 million, and a potential additional $90 million associated with approval for additional indications in the United States or for approval in other countries in North America. Cypress also agreed to fund all continuing development activities and pay BioLineRx a royalty based on applicable sales.

Ramius said poor decisions by Cypress management has damaged its stock price and that the company should hold off on making any further acquisitions or licensing deals. Shares of Cypress Bioscience are down about 73 percent over the past 12 months.

In a letter to Cypress management, Ramius said it is “ready, willing, and able to close this transaction expeditiously and expect the board to retain a reputable investment bank to immediately engage in discussions with us and any other potential acquirers to maximize value for all shareholders.”